Intended for U.S. scientific audiences only.

BMS at #EULAR2020

Pursuing the Advancement of Precision Medicines Through Biomarker Science in Immune-Mediated Diseases for Patients with Unmet Needs


A

t the European League Against Rheumatism (EULAR) 2020 Congress, we’re presenting 27 Bristol Myers Squibb-sponsored abstracts, underscoring our commitment to advancing precision medicine and developing more targeted approaches to treating immune-mediated diseases where treatment options are limited or medical unmet needs still exist. The presented data include clinical, real-world and biomarker studies that focus on furthering precision medicine in rheumatoid arthritis as well as other conditions, including juvenile idiopathic arthritis.

Check out the latest educational resources below:

Resources

Web of Discovery

Explore immune system interconnectivity.
Destination: The Impact of Precision Medicine in Disease Management for People with Immune-Mediated Diseases

Destination: The Impact of Precision Medicine in Disease Management for People with Immune-Mediated Diseases

Our Dr. Brian Gavin discusses precision medicine for immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus.
Our Precision-Focused Approach in RA and Beyond

Our Precision-Focused Approach in RA and Beyond: A Q&A with Dr. Sean E. Connolly

Our Dr. Sean E. Connolly explains our precision medicine research approach and shares a video on the potential role of biomarkers.
Disease State Infographics

Disease State Infographics

Learn about the immune-mediated diseases we’re researching.
Spotlight: Rheumatoid Arthritis

Spotlight: Rheumatoid Arthritis 

Learn more about this destructive immune-mediated disease and how it can behave differently in different people.
Spotlight: Juvenile Idiopathic Arthritis

Spotlight: Juvenile Idiopathic Arthritis

Get the facts on the most common chronic rheumatic disease affecting children and teens.